Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

相似書籍

• Oncology Drugs Approved by the FDA in Early 2018
  出版: (2018)
• FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
  由: Bradford, Diana, et al.
  出版: (2020)
• FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
  由: Anscher, Mitchell S., et al.
  出版: (2020)
• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  由: Raedler, Lisa A.
  出版: (2015)
• FDA Oncology Update
  出版: (2019)